Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 80 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 20 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 10 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 40 mg

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

allergan pharmaceuticals international limited - eluxadoline - irritable bowel syndrome; diarrhea - antidiarrheals, þarma bólgueyðandi / antiinfective lyfjum - truberzi er ætlað fullorðnum til meðferðar við einkennum einkennalausrar þarmar með niðurgangi (ibs d).

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

sanofi b.v. - eliglustat - gauchersjúkdómur - Önnur meltingarvegi og efnaskipti vörur, - cerdelga er ætlað til lengri tíma meðferð fullorðinn sjúklinga með eins sjúkdómur tegund 1 (gd1), sem eru cyp2d6 léleg metabolisers (fyrirtíðaspennu), millistig metabolisers (skilaboð) eða mikla metabolisers (sjúkrabíl).

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - Æxlishemjandi lyf - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - krabbamein, lungnakrabbamein - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

gilead sciences ireland uc - meðferð með eviplera nýrnastarfsemi alafenamide - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (hiv-1).

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

dechra regulatory b.v. - metronidazolum inn - tafla - 250 mg